The effect of biologic therapy for immune-mediated inflammatory diseases on clinical outcomes of COVID-19 in the greater Houston area: A retrospective chart review - 01/02/22
D3CODE Teamc
Omar Pacha, MD d, ⁎Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Funding sources: None. |
|
IRB approval status: Approved by the IRBs of MD Anderson and the University of Texas Health Science Center at Houston. |
|
Key words: biologics; COVID-19; cytokines; dermatology; immunosuppression; interleukins. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.